Findings of Research Misconduct, 63621-63622 [2011-26453]

Download as PDF Federal Register / Vol. 76, No. 198 / Thursday, October 13, 2011 / Notices FEDERAL RESERVE SYSTEM FEDERAL RESERVE SYSTEM Formations of, Acquisitions by, and Mergers of Bank Holding Companies Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction sroberts on DSK5SPTVN1PROD with NOTICES The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 4, 2011. A. Federal Reserve Bank of Richmond (Adam M. Drimer, Assistant Vice President) 701 East Byrd Street, Richmond, Virginia 23261–4528: 1. First Carolina Financial Services, Inc., Durham, North Carolina; to become a bank holding company by acquiring 95.26 percent of the voting securities of First Carolina State Bank, Rocky Mount, North Carolina, and 95.65 percent of the voting securities of Pisgah Community Bank, Asheville, North Carolina. Board of Governors of the Federal Reserve System, October 6, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–26433 Filed 10–12–11; 8:45 am] BILLING CODE 6210–01–P VerDate Mar<15>2010 16:50 Oct 12, 2011 Jkt 226001 This notice corrects a notice (FR Doc. 2011–25986) published on pages 62408 and 62409 of the issue for Friday, October 7, 2011. Under the Federal Reserve Bank of St. Louis heading, the entry for MutualFirst Financial, Inc., Muncie, Indiana, is revised to read as follows: A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414: 1. MutualFirst Financial, Inc., Muncie, Indiana; to become a bank holding company by acquiring 100 percent of the voting shares of MutualBank, Muncie, Indiana. Comments on this application must be received by November 4, 2011. Board of Governors of the Federal Reserve System, October 7, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–26457 Filed 10–12–11; 8:45 am] BILLING CODE 6210–01–P Formations of, Acquisitions by, and Mergers of Savings and Loan Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Home Owners’ Loan Act (12 U.S.C. 1461 et seq.) (HOLA), Regulation LL (12 CFR part 238), and Regulation MM (12 CFR part 239), and all other applicable statutes and regulations to become a savings and loan holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a savings association and nonbanking companies owned by the savings and loan holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the HOLA (12 U.S.C. 1467a(e)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 10(c)(4)(B) of the Frm 00022 Fmt 4703 HOLA (12 U.S.C. 1467a(c)(4)(B)). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 7, 2011. A. Federal Reserve Bank of Cleveland (Nadine Wallman, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101–2566: 1. Winding Creek Holdings, LLC, Toledo, Ohio; to become a savings and loan holding company by acquiring 51 percent of the voting shares of Bank of Maumee, Maumee, Ohio. Board of Governors of the Federal Reserve System, October 7, 2011. Robert deV. Frierson, Deputy Secretary of the Board. [FR Doc. 2011–26458 Filed 10–12–11; 8:45 am] BILLING CODE 6210–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary FEDERAL RESERVE SYSTEM PO 00000 63621 Sfmt 4703 Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Nicola Solomon, Ph.D., University of Michigan Medical School: Based on an investigation conducted by the University of Michigan Medical School (UMMS) and a preliminary analysis conducted by ORI, ORI found that Dr. Nicola Solomon, former postdoctoral scholar, Department of Human Genetics, UMMS, engaged in research misconduct in research supported by the National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), grants R37 HD030428 and R01 HD034283. Specifically, the Respondent did not perform DNA sequencing on 202 cDNA clones of homeobox genes to confirm their identity and integrity. Through multiple revision of the manuscript, the Respondent did not discuss this with the corresponding author or question and correct the corresponding author’s addition of text indicating that the clones had been fully sequenced and were full length or longer (as indicated in Table 3) when compared to NCBI Mus musculus Unigene. This text supported the use of the Cap-Trapper SUMMARY: E:\FR\FM\13OCN1.SGM 13OCN1 63622 Federal Register / Vol. 76, No. 198 / Thursday, October 13, 2011 / Notices technique to produce full length clones for the discovery of new genes without polymerase chain reaction (PCR). Both the Respondent and the U.S. Public Health Service (PHS) are desirous of concluding this matter without further expenditure of time and other resources and have entered into a Voluntary Settlement Agreement to resolve this matter. This settlement is not an admission of liability on the part of the Respondent. Respondent and ORI agreed to settle this matter as follows: (1) Respondent agreed that for a period of two (2) years beginning on September 16, 2011, prior to the submission of an application for PHS support for a research project on which her participation is proposed in a research capacity, and prior to her participation in this capacity on PHSsupported research, Respondent shall ensure that a plan for supervising her duties is submitted to ORI for approval; the supervision must be designed to ensure the scientific integrity of Respondent’s research contribution; Respondent agreed that she shall not participate as a researcher in any PHSsupported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; and (2) Respondent agreed to exclude herself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant, for a period of two (2) years, beginning on September 16, 2011. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2011–26453 Filed 10–12–11; 8:45 am] BILLING CODE 4150–31–P sroberts on DSK5SPTVN1PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Biodefense Science Board Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the U.S. SUMMARY: VerDate Mar<15>2010 16:50 Oct 12, 2011 Jkt 226001 Department of Health and Human Services is hereby giving notice that the National Biodefense Science Board (NBSB) will be holding a public meeting via teleconference. The meeting is open to the public. DATES: The NBSB will hold a public meeting on October 28, 2011 from 3 p.m. to 4 p.m. EST. The agenda is subject to change as priorities dictate. ADDRESSES: The meeting will occur by teleconference. To attend, call 1–866– 395–4129, pass-code ‘‘ASPR.’’ Please call 15 minutes prior to the beginning of the conference call to facilitate attendance. Individuals who wish to participate should send an email to NBSB@HHS.GOV with ‘‘NBSB Registration’’ in the subject line. FOR FURTHER INFORMATION CONTACT: Email: NBSB@HHS.GOV. SUPPLEMENTARY INFORMATION: Pursuant to section 319M of the Public Health Service Act (42 U.S.C. 247d–7f) and section 222 of the Public Health Service Act (42 U.S.C. 217a), the Department of Health and Human Services established the National Biodefense Science Board. The Board shall provide expert advice and guidance to the Secretary on scientific, technical, and other matters of special interest to the Department of Health and Human Services regarding current and future chemical, biological, nuclear, and radiological agents, whether naturally occurring, accidental, or deliberate. The Board may also provide advice and guidance to the Secretary and/or the Assistant Secretary for Preparedness and Response on other matters related to public health emergency preparedness and response. Background: The majority of this public meeting teleconference will be dedicated to a discussion of the report and recommendations from the NBSB’s Anthrax Vaccine Working Group. Subsequent agenda topics will be added as priorities dictate. Any additional agenda topics will be available on the Board’s October meeting Web page prior to the public meeting. Availability of Materials: The meeting agenda and materials will be posted prior to the meeting on the October meeting Web page at https:// www.phe.gov/preparedness/legal/ boards/nbsb/pages/default.aspx. Procedures for Providing Public Input: Members of the public are invited to attend by teleconference via a toll-free call-in phone number. The teleconference will be operator assisted to allow the public the opportunity to provide comments to the Board. Public participation will be limited to time and space available. Public comments will be limited to no more than 3 minutes PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 per speaker. To be placed on the public comment list, notify the operator when you join the teleconference. Public comments received by close of business one week prior to each teleconference will be distributed to the NBSB in advance. Submit comments via email to NBSB@HHS.GOV, with ‘‘NBSB Public Comment’’ as the subject line. Dated: October 5, 2011. Nicole Lurie, Assistant Secretary for Preparedness and Response. [FR Doc. 2011–26389 Filed 10–12–11; 8:45 am] BILLING CODE 4150–37–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Healthcare Infection Control Practices Advisory Committee, (HICPAC) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting for the aforementioned committee: Times and Dates: 9 a.m.–5 p.m., November 3, 2011. 9 a.m.–12 p.m., November 4, 2011. Place: Embassy Suites-Washington, DC Convention Center, Capital CD Room, 900 10th Street, NW., Washington, DC 2000. Status: Open to the public, limited only by the space available. Please register for the meeting at https://www.cdc.gov/hicpac. Purpose: The Committee is charged with providing advice and guidance to the Secretary, the Assistant Secretary for Health, the Director, CDC, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), and the Director, Division of Healthcare Quality Promotion regarding (1) The practice of healthcare infection control; (2) strategies for surveillance, prevention, and control of infections (e.g., nosocomial infections), antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions. Matters To Be Discussed: The agenda will include updates on CDC’s activities for healthcare associated infections, draft guideline for prevention of infections among patients in neonatal intensive care units (NICU), draft guideline for infection control in healthcare personnel, draft guideline for the prevention of surgical site infections, update from the HICPAC surveillance working group, and guidance for control of Carbapenem-resistant Enterobacteriaceae. Agenda items are subject to change as priorities dictate. For Further Information Contact: Heidi Williams, HICPAC, Division of Healthcare E:\FR\FM\13OCN1.SGM 13OCN1

Agencies

[Federal Register Volume 76, Number 198 (Thursday, October 13, 2011)]
[Notices]
[Pages 63621-63622]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-26453]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Nicola Solomon, Ph.D., University of Michigan Medical School: Based 
on an investigation conducted by the University of Michigan Medical 
School (UMMS) and a preliminary analysis conducted by ORI, ORI found 
that Dr. Nicola Solomon, former postdoctoral scholar, Department of 
Human Genetics, UMMS, engaged in research misconduct in research 
supported by the National Institute of Child Health and Human 
Development (NICHD), National Institutes of Health (NIH), grants R37 
HD030428 and R01 HD034283.
    Specifically, the Respondent did not perform DNA sequencing on 202 
cDNA clones of homeobox genes to confirm their identity and integrity. 
Through multiple revision of the manuscript, the Respondent did not 
discuss this with the corresponding author or question and correct the 
corresponding author's addition of text indicating that the clones had 
been fully sequenced and were full length or longer (as indicated in 
Table 3) when compared to NCBI Mus musculus Unigene. This text 
supported the use of the Cap-Trapper

[[Page 63622]]

technique to produce full length clones for the discovery of new genes 
without polymerase chain reaction (PCR).
    Both the Respondent and the U.S. Public Health Service (PHS) are 
desirous of concluding this matter without further expenditure of time 
and other resources and have entered into a Voluntary Settlement 
Agreement to resolve this matter. This settlement is not an admission 
of liability on the part of the Respondent.
    Respondent and ORI agreed to settle this matter as follows:
    (1) Respondent agreed that for a period of two (2) years beginning 
on September 16, 2011, prior to the submission of an application for 
PHS support for a research project on which her participation is 
proposed in a research capacity, and prior to her participation in this 
capacity on PHS-supported research, Respondent shall ensure that a plan 
for supervising her duties is submitted to ORI for approval; the 
supervision must be designed to ensure the scientific integrity of 
Respondent's research contribution; Respondent agreed that she shall 
not participate as a researcher in any PHS-supported research until 
such a supervision plan is submitted to and approved by ORI; Respondent 
agreed to maintain responsibility for compliance with the agreed upon 
supervision plan; and
    (2) Respondent agreed to exclude herself from serving in any 
advisory capacity to PHS including, but not limited to, service on any 
PHS advisory committee, board, and/or peer review committee, or as a 
consultant, for a period of two (2) years, beginning on September 16, 
2011.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2011-26453 Filed 10-12-11; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.